- Home
- STKS vs RAPT Comparison
STKS vs RAPT Comparison
Compare STKS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- RAPT
- Stock Information
- Founded
- STKS 2004
- RAPT 2015
- Country
- STKS United States
- RAPT United States
- Employees
- STKS N/A
- RAPT N/A
- Industry
- STKS Restaurants
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- RAPT Health Care
- Exchange
- STKS Nasdaq
- RAPT Nasdaq
- Market Cap
- STKS 112.2M
- RAPT 122.9M
- IPO Year
- STKS N/A
- RAPT 2019
- Fundamental
- Price
- STKS $4.05
- RAPT $8.04
- Analyst Decision
- STKS Buy
- RAPT Buy
- Analyst Count
- STKS 2
- RAPT 5
- Target Price
- STKS $4.25
- RAPT $42.00
- AVG Volume (30 Days)
- STKS 224.7K
- RAPT 109.8K
- Earning Date
- STKS 08-05-2025
- RAPT 08-07-2025
- Dividend Yield
- STKS N/A
- RAPT N/A
- EPS Growth
- STKS N/A
- RAPT N/A
- EPS
- STKS N/A
- RAPT N/A
- Revenue
- STKS $799,478,000.00
- RAPT N/A
- Revenue This Year
- STKS $28.67
- RAPT N/A
- Revenue Next Year
- STKS $5.12
- RAPT N/A
- P/E Ratio
- STKS N/A
- RAPT N/A
- Revenue Growth
- STKS 138.50
- RAPT N/A
- 52 Week Low
- STKS $2.37
- RAPT $5.67
- 52 Week High
- STKS $5.42
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- STKS 65.81
- RAPT 62.95
- Support Level
- STKS $4.01
- RAPT $7.04
- Resistance Level
- STKS $3.80
- RAPT $8.91
- Average True Range (ATR)
- STKS 0.32
- RAPT 0.84
- MACD
- STKS 0.08
- RAPT 0.08
- Stochastic Oscillator
- STKS 89.04
- RAPT 92.53
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.